VivoSeq
Oncology

Colorectal Neoplasms

17

Pipeline Programs↗

10

Active Trials↗

9

Companies Involved↗

Colorectal Neoplasms is an emerging landscape with 17 programs across 9 companies. The most active players are Amgen, Glaxo Dba Glaxosmithkline, AstraZeneca. 8 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

15/100

Mech. Concentration

25/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

1 program

Phase 1G

Glaxo Dba Glaxosmithkline

1 program

Phase 1AstraZeneca logo

AstraZeneca

4 programs

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 3Teva logo

Teva

1 program

Phase 3I

Imclone

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

12 of 16 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody425%

Small molecule leads; the ring shows all 16 classified programs, each share of the total. Modality classified for 94% of 17 pipeline programs.

Analysis

Trial Status

11

clinical trials

Recruiting7 · 64%
Active, not recruiting2 · 18%
Completed1 · 9%
Not yet recruiting1 · 9%

Clinical Trials

Trial Activity

11 trials

Tumor, Normal Tissue and Specimens From Patients Undergoing Evaluation or Surgical Resection of Solid Tumors
Recruiting·National Cancer Institute (NCI)·N/A·NCT01915225·1,800 enrolled
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT06662786·1,000 enrolled
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT06750094·700 enrolled
An Open-label Phase 1 Study to Investigate PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors
Recruiting·Pfizer logoPfizer·Phase 1·NCT06131840·914 enrolled
A Phase 1 Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT07107230·380 enrolled
A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer and Other Gastrointestinal Malignancies
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT06663319·260 enrolled
Impact of SMS Notifications on the Colorectal Cancer Screening Program
Recruiting·CCorporacion Parc Tauli·Preclinical·NCT07628998·10,084 enrolled
Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
Active, not recruiting·National Cancer Institute (NCI)·Preclinical·NCT02484404·268 enrolled
MyGI Diet for Colorectal Cancer Prevention
Active, not recruiting·UUniversity of Michigan·Preclinical·NCT05396846·240 enrolled
Preventing Early-Onset Colorectal Cancer in the VA Using a Multilevel Screening Intervention
Not yet recruiting·VVA Office of Research and Development·Preclinical·NCT07071454·536 enrolled
Physical Activity Intervention Co-created and Tested With African American Colorectal Cancer Survivors
Completed·UUNC Lineberger Comprehensive Cancer Center·Preclinical·NCT06411756·21 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)